APEX1 and cancer: Recently, we have carried out a meta-analysis on all eligible case-control studies to estimate the APE1 T1349G polymorphism and risk of cancers, including lung cancer, bladder cancer, colorectal cancer, breast cancer, pancreatic cancer, head and neck cancer, leukaemia, esophageal cancer, biliary tract cancer, thyroid cancer, and prostate cancer [13].